Latest Headlines
-
5 Biologics Conferences You Won’t Want To Miss In 2024
2/23/2024
This list of recommended biologics conferences for 2024 can help guide professionals in the biologics industry to the most relevant and influential conferences for their professional goals.
-
AES Clean Technology Appoints New Vice President Of Engineering
2/22/2024
AES Clean Technology, a leading provider of high-performance modular cleanroom facilities, has appointed Chris Barbieri as Vice President of Engineering.
-
WuXi Advanced Therapies Receives FDA Approval To Manufacture Iovance’s AMTAGVI™ (lifileucel) For Advanced Melanoma
2/20/2024
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License Application (BLA) on February 16, 2024.
-
Eppendorf Innovation Company Strengthens Access To U.S. Start-Up Scene
2/14/2024
The Eppendorf Innovation Company (EpIC) – a division of Eppendorf SE – continues to expand its international network. Through a targeted investment in Osage University Partners (OUP), EpIC will learn about investment opportunities in some of the most cutting-edge startups transitioning their academic discoveries into the commercial world through OUP’s network of university spinouts.
-
INCOG BioPharma Services Adds 100 Million Units Of Syringe/Cartridge Capacity
2/14/2024
INCOG BioPharma Services, a US-based contract development and manufacturing organization (CDMO) specializing in sterile injectables, is adding a high-speed OPTIMA filling line that will provide an additional 100 million units of syringe and cartridge filling capacity.
-
Analytical Platform LabZient™, Expedites The Path To IND For Antibodies
2/7/2024
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its new analytical platform, LabZient™. The standardized and automated platform streamlines the assessment and validation of large molecules, which significantly reduces drug development timelines and resource costs.
-
Waisman Biomanufacturing & RoosterBio Announce Collaboration For GMP Manufacturing of Cell & Exosome Therapies
2/6/2024
Waisman Biomanufacturing, a leading contract development and manufacturing organization (CDMO) which is strategically part of the University of Wisconsin Madison, announced today a strategic partnership with RoosterBio, Inc., a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.
-
Purolite And Repligen Announce The Commercial Launch Of A Novel CH1 Affinity Resin For The Purification Of Specialized mAbs
2/6/2024
Purolite, an Ecolab company and leading manufacturer of synthetic and agarose-based bioprocessing resins, and Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of Praesto® CH1, a new 70μm (micron) agarose-based affinity resin designed to purify specialized mAbs such as bispecifics and recombinant antibody fragments.
-
Novo Holdings To Acquire CDMO Catalent Pharma Solutions For $16.5 Billion
2/5/2024
Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, today announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.
-
Solesis, Parent Company of Charter Medical, to Expand Single-use Manufacturing Capabilities into Costa Rica
2/2/2024
The site will expand capabilities to enable development in the fast-growing cardiovascular and advanced therapy markets.